Drugs / 608
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT05536726 | Jan → Oct 2023 | psoriasis | Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | 608 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05536726 ↗ |
| Action | Inhibit | “anti-IL-17A” NCT05536726 ↗ |
| Modality | Monoclonal antibody | “recombinant anti-IL-17A humanized monoclonal antibody” NCT05536726 ↗ |
| Route | Subcutaneous | “by subcutaneous injection” NCT05536726 ↗ |
| Target | IL17A | “anti-IL-17A” NCT05536726 ↗ |